Retinoic acid stimulates myocardial expansion by induction of hepatic erythropoietin which activates epicardial Igf2.
Epicardial signaling and Rxra are required for expansion of the ventricular myocardial compact zone. Here, we examine Raldh2(-/-) and Rxra(-/-) mouse embryos to investigate the role of retinoic acid (RA) signaling in this developmental process. The heart phenotypes of Raldh2 and Rxra mutants are very similar and are characterized by a prominent defect in ventricular compact zone growth. Although RA activity is completely lost in Raldh2(-/-) epicardium and the adjacent myocardium, RA activity is not lost in Rxra(-/-) hearts, suggesting that RA signaling in the epicardium/myocardium is not required for myocardial compact zone formation. We explored the possibility that RA-mediated target gene transcription in non-cardiac tissues is required for this process. We found that hepatic expression of erythropoietin (EPO), a secreted factor implicated in myocardial expansion, is dependent on both Raldh2 and Rxra. Chromatin immunoprecipitation studies support Epo as a direct target of RA signaling in embryonic liver. Treatment of an epicardial cell line with EPO, but not RA, upregulates Igf2. Furthermore, both Raldh2(-/-) and Rxra(-/-) hearts exhibit downregulation of Igf2 mRNA in the epicardium. EPO treatment of cultured Raldh2(-/-) hearts restores epicardial Igf2 expression and rescues ventricular cardiomyocyte proliferation. We propose a new model for the mechanism of RA-mediated myocardial expansion in which RA directly induces hepatic Epo resulting in activation of epicardial Igf2 that stimulates compact zone growth. This RA-EPO-IGF2 signaling axis coordinates liver hematopoiesis with heart development.
Sanford-Burnham Medical Research Institute, Development and Aging Program, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA.
Thomas
T
Brade
Sandeep
S
Kumar
Thomas J
TJ
Cunningham
Christina
C
Chatzi
Xianling
X
Zhao
Susana
S
Cavallero
Peng
P
Li
Henry M
HM
Sucov
Pilar
P
Ruiz-Lozano
Gregg
G
Duester
D000445:Aldehyde Oxidoreductases / Q000235:genetics / Q000378:metabolism; D000818:Animals; D002478:Cells, Cultured; D047369:Chromatin Immunoprecipitation; D004921:Erythropoietin / Q000235:genetics / Q000378:metabolism*; D006321:Heart / Q000187:drug effects / Q000196:embryology; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D007335:Insulin-Like Growth Factor II / Q000235:genetics / Q000378:metabolism*; D007641:Keratolytic Agents / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009206:Myocardium / Q000378:metabolism*; D009924:Organ Culture Techniques; D010496:Pericardium / Q000187:drug effects / Q000378:metabolism*; D047490:Retinoid X Receptor alpha / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014212:Tretinoin / Q000494:pharmacology*
C513121:IGF2 protein, mouse; D007641:Keratolytic Agents; D047490:Retinoid X Receptor alpha; D004921:Erythropoietin; D014212:Tretinoin; D007335:Insulin-Like Growth Factor II; D000445:Aldehyde Oxidoreductases; C470579:RALDH2 protein, mouse